Axol Bioscience Secures $2.8M to Develop iPSC Models
The latest funding round will support US expansion, new stem cell-derived disease models, and increased manufacturing at its Edinburgh site.
Key findings
- Axol Bioscience has raised $2.8 million to expand its US operations and develop new induced pluripotent stem cell (iPSC) disease models in neuroscience, ophthalmology, and cardiovascular research.
- Axol also plans to scale up cell manufacturing at its Roslin Innovation Centre site in Edinburgh.
Stay updated on Neuroregeneration news
Thanks! Your signup has been saved.
Axol Bioscience has secured $2.8 million (£2.1 million) in funding, led by BroadOak Capital Partners, with participation from the company’s founding investor, the Roslin Foundation.
What the funding will support
Axol says the investment will support the expansion of its US footprint and product portfolio. The company plans to develop enhanced in vitro disease models for neuroscience, ophthalmology, and cardiovascular disease, and increase manufacturing capacity at its Roslin Innovation Centre in the UK.
What Axol does
Axol develops and supplies induced pluripotent stem cell (iPSC) derived cells, along with reagents and specialist services. The company sells to pharmaceutical and biotech companies, contract research organizations (CROs), and academic institutions.
Axol also says it has focused on building physiologically relevant iPSC-derived models for neurodegenerative disorders, including Huntington’s disease and sporadic amyotrophic lateral sclerosis.
What executives and investors said
“Following Axol’s 45% revenue growth in 2025 and 36% in 2024, this funding allows us to strengthen our US operations and expand manufacturing capacity at our Edinburgh site, ensuring we can continue to meet increasing global demand,” added Oliver Richardson, CFO of Axol Bioscience.
Recent momentum
Axol says the raise follows a period of commercial growth and continued investment in manufacturing and quality systems at its Edinburgh, UK facility, alongside expanded relationships with global pharmaceutical partners and a larger US market presence.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
Encellin and Breakthrough T1D Planning Phase 1 of Immune-Protected Cell Therapy for Type 1 Diabetes
Webinar: Scaling iPSC Therapies Without Scaling VariabilityOn-Demand
Aspen Neuroscience Publishes Preclinical Data on Parkinson’s iPSC-Derived Cell Therapy
Made Scientific Acquires Resilience’s 85K-Square-Foot Cell Therapy FacilityEditor’s Picks
Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND Soon
Umbilical Cord Mesenchymal Stem Cell Injections Lower Pain Scores More Than Hyaluronate in 50-Patient Severe Knee Osteoarthritis Trial
Stempeutics Nabs US Patent for Osteoarthritis Treatment Combining Bone Marrow Stem Cells and Hyaluronic Acid
Novadip Secures €10.4M for Pivotal Phase 3 Bone Repair Cell Therapy Trial
